Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia

Bone Marrow Transplantation volume 34, pages 667–673 (2004)Cite this article

Summary:

Between September 1986 and June 1997, 24 children with high-risk ALL in CR1 were allografted after TAM (fractionated TBI, high-dose Ara-C, and melphalan; n=10) or BAM protocol (busulfan, high-dose Ara-C, and melphalan; n=14). The EFS for transplants from sibling donors was 33% with TAM and 62% with BAM (P=0.148). The probability of acute GvHD was 70% with TAM and 15% with BAM (P=0.003). Four of 17 evaluable patients relapsed: one after TAM and three after BAM. In all, 46 other children transplanted in CR beyond CR1 were studied for sequelae. Long-term side effects were more frequent in TAM vs BAM. In children with ALL, busulfan may be a good alternative to TBI to improve the quality of life.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kersey JH . Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243–4251.

    CAS  PubMed  Google Scholar 

  2. Pinkel D . Treatment of acute lymphoblastic leukemia in a second remission. New Engl J Med 1995; 332: 823–826.

    CAS  PubMed  Google Scholar 

  3. Dini G, Cornish JM, Gadner H et al. Bone marrow transplant indications for childhood leukemia: achieving a consensus. Bone Marrow Transplant 1996; 18: 4–7.

    PubMed  Google Scholar 

  4. Brochstein JA, Kernan NA, Groshen S et al. Allogeneic bone marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukemiac. New Engl J Med 1987; 317: 1618–1624.

    Article  CAS  PubMed  Google Scholar 

  5. Blume KG, Forman SJ, O'Donnel MR et al. Total body irradiation and high-dose etoposide: a new preparative regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015–1020.

    CAS  PubMed  Google Scholar 

  6. Coccia PF, Strandjord SE, Warkentin PI et al. High dose cytosine arabinoside and fractioned total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 1988; 71: 888–893.

    CAS  PubMed  Google Scholar 

  7. Bordigoni P, Esperou H, Souillet G et al. Total body irradiation, high dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukemia after relapse while receiving chemotherapy: a Societe Francaise de Greffe de Moelle study. Br J Haematol 1998; 102: 656–665.

    Article  CAS  PubMed  Google Scholar 

  8. Sanders JE, Pritchard S, Mahoney P et al. Growth and development following marrow transplantation for leukemia. Blood 1986; 68: 1129–1135.

    CAS  PubMed  Google Scholar 

  9. Sanders JE, Bucker CD, Leonard JM et al. Late effects on gonadal function of cyclophosphamide, total body irradiation, and marrow transplantation. Transplantation 1983; 36: 252–255.

    Article  CAS  PubMed  Google Scholar 

  10. Sklar CA, Kim TH, Ramsay NKC et al. Thyroid dysfunction among long-term survivors of bone marrow transplantation. Am J Med 1982; 73: 688–694.

    Article  CAS  PubMed  Google Scholar 

  11. Von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the Societé Francaise de Greffe de Moelle. Bone Marrow Transplant 1995; 16: 521–527.

    CAS  PubMed  Google Scholar 

  12. Matsuyama T Kojima S, Kato K . Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant 1998; 22: 21–26.

    Article  PubMed  Google Scholar 

  13. Vilmer E, Suciu S, Ferster A et al. Long term results of three randomized trials (58831,58832,58881) in childhood acute lymphocytic leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257–2266.

    Article  CAS  PubMed  Google Scholar 

  14. Bordigoni P, Vernant JP, Souillet G et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the group d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 1989; 7: 747–753.

    Article  CAS  PubMed  Google Scholar 

  15. Saarinen UM, Mellander L, Nyson K et al. Allogeneic bone marrow transplantation in first remission for children with very high risk acute lymphoblastic leukemia: a retrospective case control-study in Nordic countries (NOPHO). Bone Marrow Transplant 1996; 17: 357–363.

    CAS  PubMed  Google Scholar 

  16. Uderzo C, Valsecchi MG, Balduzzi A et al. Allogeneic bone marrow transplantation versus chemotherapy in high risk childhood acute lymphoblastic leukemia in first remission. Br J Haematol 1997; 96: 387–394.

    Article  CAS  PubMed  Google Scholar 

  17. Wheeler KA, Richards SM, Bailley CC et al. Bone marrow transplantation versus chemotherapy in the treatment of very high risk childhood acute lymphoblastic leukemia in first remission: result from Medical Research Council UKALL X an XI. Blood 2000; 96: 2412–2418.

    CAS  PubMed  Google Scholar 

  18. Sadowitz PD, Smith SD, Shuster J et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1993; 81: 602–609.

    CAS  PubMed  Google Scholar 

  19. Boulad F, Steinherz P, Reyes B et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution Study. J Clin Oncol 1999; 17: 197–207.

    Article  CAS  PubMed  Google Scholar 

  20. Gordon BG, Warkentin PI, Strandjord SE et al. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation. Bone Marrow Transplant 1997; 20: 5–10.

    Article  CAS  PubMed  Google Scholar 

  21. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730.

    PubMed  Google Scholar 

  22. Ringdén O, Labopin M, Tura S et al. A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Br J Haematol 1996; 93: 637–645.

    Article  PubMed  Google Scholar 

  23. Davies SM, Ramsay NCK, Klein JP et al. Comparison of preparative regimens, in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.

    Article  CAS  PubMed  Google Scholar 

  24. Mineishi S, Longo WL, Atkinson ME et al. Addition of high-dose Ara C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant 1999; 23: 1217–1222.

    Article  CAS  PubMed  Google Scholar 

  25. Sklar C . Growth and endocrine disturbance after bone marrow transplantation in childhood. Acta Paediatr Suppl 1995; 411: 57–61.

    Article  CAS  PubMed  Google Scholar 

  26. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784–789.

    Article  CAS  PubMed  Google Scholar 

  27. Shalet SM, Didi M, Ogilvy-Stuart et al. Growth and endocrine function after bone marrow transplantation. Clin Endocrinol 1995; 42: 333–339.

    Article  CAS  Google Scholar 

  28. Wingard JR, Piotnick LP, Freemer CS et al. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 1992; 79: 1068–1073.

    CAS  PubMed  Google Scholar 

  29. Michel G, Solié G, Gebhard F et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first remission: the impact of conditioning regimen without total body irradiation. A report from the Société Française de Greffe de Moelle. J Clin Oncol 1997; 15: 2238–2246.

    Article  CAS  PubMed  Google Scholar 

  30. Dahllöf G, Barr M, Bolme P et al. Disturbance in tental development after total body irradiation in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1988; 65: 4144.

    Article  Google Scholar 

  31. Bruno B, Souillet G, Bertrand Y et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004; 7: 1043–1057.

    Google Scholar 

  32. Bleyzac N, Souillet G, Magron P et al. Improved clinical outcome of pediatric bone marrow recipients by using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone marrow transplantation. 2001; 28: 743–751.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics, Shanghai Second Medical University, Ruijin Hospital, China

    Q Y Dai

  2. Immuno-hematology and Bone Marrow Transplantation, Debrousse Hospital, Lyon, France

    G Souillet, Y Bertrand, C Galambrun, A M Manel, B Bruno, A L Souillet, E Homole, M P Pages & N Philippe

  3. Department of Pharmacy, Debrousse Hospital, Lyon, France

    N Bleyzac

  4. Department of Endocrinology, Debrousse Hospital, Lyon, France

    P Berlier

  5. Paediatric intensive care unit, Debrousse Hospital, Lyon, France

    M David, J C Berthier, B Massenavette & B Contamin

Authors
  1. Q Y Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Souillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Galambrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Bleyzac
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A M Manel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A L Souillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Homole
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M P Pages
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Berlier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M David
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J C Berthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. B Massenavette
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. B Contamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. N Philippe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Souillet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dai, Q., Souillet, G., Bertrand, Y. et al. Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Bone Marrow Transplant 34, 667–673 (2004). https://doi.org/10.1038/sj.bmt.1704605

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704605

Keywords

This article is cited by

Search

Advanced search

Quick links